Medical Data Vision Cash Flow Statement

Financials in millions JPY. Fiscal year is January - December.

Millions JPY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	65	-727	1,567	1,426	1,591
Depreciation & Amortization	108	127	101	149	135
Loss (Gain) From Sale of Assets	4	4	116	375	1
Loss (Gain) From Sale of Investments	290	127	15	-51	-
Loss (Gain) on Equity Investments	5	514	72	-	-
Other Operating Activities	121	-754	-253	-672	-471
Change in Accounts Receivable	-96	85	-167	-282	-190
Change in Inventory	-24	-16	10	-	24
Change in Accounts Payable	31	82	83	-4	6
Change in Other Net Operating Assets	278	-319	72	-31	-14
Operating Cash Flow	782	-877	1,616	910	1,082
Operating Cash Flow Growth	-	-	77.58%	-15.90%	12.24%
Capital Expenditures	-62	-154	-30	-53	-24
Investment in Securities	-	-301	-393	-799	-2
Other Investing Activities	-28	-17	-14	-16	-
Investing Cash Flow	-96	-592	-437	-868	-26
Issuance of Common Stock	-	1	3	-	-
Repurchase of Common Stock	-	-153	-	-871	-889
Common Dividends Paid	-245	-248	-228	-217	-141
Other Financing Activities	-74	1	-	109	-
Financing Cash Flow	-319	-399	-225	-979	-1,030
Miscellaneous Cash Flow Adjustments	-2	-2	-1	-	-1
Net Cash Flow	365	-1,870	953	-937	25
Free Cash Flow	720	-1,031	1,586	857	1,058
Free Cash Flow Growth	-	-	85.06%	-19.00%	12.79%
Free Cash Flow Margin	11.01%	-17.46%	24.71%	14.04%	18.65%
Free Cash Flow Per Share	19.02	-27.02	41.52	22.41	27.00
Cash Income Tax Paid	-117	759	258	670	471
Levered Free Cash Flow	459	-712.13	1,593	1,202	1,072
Unlevered Free Cash Flow	459	-712.13	1,593	1,202	1,072
Change in Working Capital	189	-168	-2	-317	-174

Source: S&P Global Market Intelligence. Standard template. Financial Sources.